Epoch Investment Partners Inc. Has $56.01 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Epoch Investment Partners Inc. raised its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 271,144 shares of the medical research company’s stock after purchasing an additional 23,643 shares during the period. Epoch Investment Partners Inc. owned 0.53% of Charles River Laboratories International worth $56,013,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Tortoise Investment Management LLC lifted its stake in shares of Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 57 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Charles River Laboratories International during the 1st quarter worth about $41,000. Brown Brothers Harriman & Co. boosted its stake in shares of Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after acquiring an additional 95 shares in the last quarter. Whittier Trust Co. of Nevada Inc. increased its holdings in shares of Charles River Laboratories International by 219.3% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 193 shares during the last quarter. Finally, Concord Wealth Partners raised its stake in shares of Charles River Laboratories International by 362.5% in the 1st quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 203 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on CRL. StockNews.com upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Tuesday, August 20th. Evercore ISI lowered their target price on shares of Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. The Goldman Sachs Group cut their target price on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Mizuho started coverage on Charles River Laboratories International in a research report on Friday, June 7th. They issued a “neutral” rating and a $235.00 price target on the stock. Finally, UBS Group cut their price objective on Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Ten equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $227.55.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $205.79 on Monday. The business’s 50 day moving average is $209.34 and its 200-day moving average is $223.52. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $10.60 billion, a PE ratio of 24.21, a PEG ratio of 3.89 and a beta of 1.36. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.41. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.03 billion. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current year.

Charles River Laboratories International declared that its board has initiated a stock buyback program on Wednesday, August 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 9.6% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).